Category Archives: AZBio News
BIO Announces New Strategic Vision
BIO announces new, strategic direction that will help guide it to achieving long-term goals while maintaining responsiveness to changing political headwinds
FDA Awards C-Path Grant to Use Real-World Data to Generate Real-World Evidence in Neonates
Pilot project will include the development of a Real-World Data and Analytics Platform
TUCSON, Ariz., October 27, 2020 — Arizona-based Critical Path Institute (C-Path) is pleased to announce it has been awarded a multi-year grant by the U.S. Food and Drug Administration (FDA) to advance standards and methodologies designed to generate real-world evidence (RWE) from real-world data (RWD) through a neonatal pilot project through the International Neonatal Consortium (INC).Continue reading
HybridChart Announces Partnership with PointClickCare
Partnership to Integrate HybridChart’s Rounding and Workflow Solution with PointClickCare’s EHR PlatformContinue reading
AZBio Issues RFP for a Marketing Consultant to Support the AZAdvances Capital Campaign
Access to early stage growth capital is an ongoing challenge to the growth of Arizona’s Bioindustry. To address this challenge, AZBio, in partnership with the Opportunity Through Entrepreneurship Foundation and with support from a US. Economic Development Agency (EDA) grant has developed AZAdvances. The Marketing Consultant will work with the AZBio Team to inspire the community and engage support.Continue reading
AZBio Job Opportunity: Entrepreneurial Program Grants Administrator (Post-doc)
As part of its ongoing efforts to strengthen Arizona’s Bioscience and Medtech Entrepreneurial Ecosystem, AZBio encourages qualified post-doctorate applicants to apply to join our team as a Entrepreneurial Program Grants Administrator. This is a 1-year position.Continue reading
AZBio Job Opportunity: Entrepreneur in Residence
As part of its ongoing efforts to strengthen Arizona’s Bioscience and Medtech Entrepreneurial Ecosystem, AZBio encourages qualified applicants to apply to join our team as a Bioscience Entrepreneur-in-Residence (EIR).Continue reading
Online applications for the 2021 virtual KEYS program will open on November 1 and close December 6.
2021 KEYS PROGRAM | JUNE 7 – JULY 23, 2021
U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19
— Veklury Is First and Only FDA-Approved Treatment for COVID-19 in the United States —
— Veklury Shortened Time to Recovery By Five Days in Hospitalized COVID-19 Patients —
Rare Disease Cures Accelerator-Data and Analytics Platform First Year Milestones Highlighted at Virtual Workshop
C-Path, NORD, FDA and more come together to showcase the importance of data sharing in rare disease drug development
TUCSON, Ariz. and WASHINGTON, D.C. October 21, 2020 — The Critical Path Institute (C-Path) and the National Organization for Rare Disorders (NORD®) hosted the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) 2020 Virtual Workshop on Monday, October 19. The platform, funded by a cooperative agreement through the U.S. Food and Drug Administration (FDA), serves as a centralized and standardized infrastructure to support data sharing and data analysis to aid in the understanding of rare diseases.Continue reading